Purpose: To evaluate the safety, efficacy, and clinical outcomes of wavefront-guided laser in situ keratomileusis (LASIK) surgery for the treatment of moderate to high myopia and compound myopic astigmatism.
Setting: Stanford University School of Medicine, Department of Ophthalmology, Stanford, California, USA.
Methods: This retrospective study included patients with moderate (-6.0 to -8.0 diopters [D]) and high (greater than -8.00) myopia treated with wavefront-guided LASIK using the WaveScan linked to the CustomVue system (AMO USA, Inc.). Eyes were analyzed preoperatively and 1, 3, and 12 months postoperatively.
Results: The mean patient age was 38.4 years +/- 7.14 (SD). Eighty-nine eyes of 45 patients were evaluated at 3 months and 50 eyes of 25 patients at 12 months. No eye was retreated during the study. The mean manifest refraction spherical equivalent was -8.10 +/- 0.98 D (range -6.00 to -10.63 D) preoperatively and -0.33 +/- 0.55 D (range -1.625 to 1.375 D) 12 months postoperatively. Ninety percent of the eyes were within +/-1.00 D of the intended correction and 64.0%, within +/-0.50 D. For all eyes, the safety index was 1.00 and the efficacy index, 1.18.
Conclusion: The data support the safety and efficacy of correcting moderate to high myopia and compound myopic astigmatism using wavefront-guided LASIK.